These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19071184)

  • 21. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8.
    Saito T; Fujii T; Kanatani Y; Saijo M; Morikawa S; Yokote H; Takeuchi T; Kuwabara N
    JAMA; 2009 Mar; 301(10):1025-33. PubMed ID: 19278946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and immunological comparison of smallpox vaccine administered to the outer versus the inner upper arms of vaccinia-naive adults.
    Waibel KH; Golding H; Manischewitz J; King LR; Tuchscherer M; Topolski RL; Walsh DS
    Clin Infect Dis; 2006 Feb; 42(4):e16-20. PubMed ID: 16421781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of human immunological responses to vaccinia virus.
    Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
    Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination.
    Ennis FA; Cruz J; Demkowicz WE; Rothman AL; McClain DJ
    J Infect Dis; 2002 Jun; 185(11):1657-9. PubMed ID: 12023773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults.
    Treanor J; Wu H; Liang H; Topham DJ
    Vaccine; 2006 Nov; 24(47-48):6913-23. PubMed ID: 17014939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.
    Pittman PR; Garman PM; Kim SH; Schmader TJ; Nieding WJ; Pike JG; Knight R; Johnston SC; Huggins JW; Kortepeter MG; Korman L; Ranadive M; Quinn X; Meyers MS
    Vaccine; 2015 Jun; 33(26):2990-6. PubMed ID: 25930115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age distribution for T cell reactivity to vaccinia virus in a healthy population.
    Hsieh SM; Pan SC; Chen SY; Huang PF; Chang SC
    Clin Infect Dis; 2004 Jan; 38(1):86-9. PubMed ID: 14679452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers.
    Jang HC; Kim CJ; Kim KH; Lee KH; Byun YH; Seong BL; Saletti G; Czerkinsky C; Park WB; Park SW; Kim HB; Kim NJ; Oh MD
    Vaccine; 2010 Aug; 28(36):5845-9. PubMed ID: 20600480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutting edge: mucosal application of a lyophilized viral vector vaccine confers systemic and protective immunity toward intracellular pathogens.
    Kastenmuller W; Gasteiger G; Stross L; Busch DH; Drexler I
    J Immunol; 2009 Mar; 182(5):2573-7. PubMed ID: 19234150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to smallpox vaccine in persons immunized in the distant past.
    Frey SE; Newman FK; Yan L; Lottenbach KR; Belshe RB
    JAMA; 2003 Jun; 289(24):3295-9. PubMed ID: 12824212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
    Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
    Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.
    Jones-Trower A; Garcia A; Meseda CA; He Y; Weiss C; Kumar A; Weir JP; Merchlinsky M
    Virology; 2005 Dec; 343(1):128-40. PubMed ID: 16165184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3.
    Osborne JD; Da Silva M; Frace AM; Sammons SA; Olsen-Rasmussen M; Upton C; Buller RM; Chen N; Feng Z; Roper RL; Liu J; Pougatcheva S; Chen W; Wohlhueter RM; Esposito JJ
    Vaccine; 2007 Dec; 25(52):8807-32. PubMed ID: 18037545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioterrorism. Smallpox vaccinations: how much protection remains?
    Cohen J
    Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
    [No Abstract]   [Full Text] [Related]  

  • 36. Unintentional transfer of vaccinia virus associated with smallpox vaccines: ACAM2000(®) compared with Dryvax(®).
    Tack DM; Karem KL; Montgomery JR; Collins L; Bryant-Genevier MG; Tiernan R; Cano M; Lewis P; Engler RJ; Damon IK; Reynolds MG
    Hum Vaccin Immunother; 2013 Jul; 9(7):1489-96. PubMed ID: 23571177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events following smallpox vaccination with ACAM2000 in a military population.
    Beachkofsky TM; Carrizales SC; Bidinger JJ; Hrncir DE; Whittemore DE; Hivnor CM
    Arch Dermatol; 2010 Jun; 146(6):656-61. PubMed ID: 20566929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.
    Kan VL; Manischewitz J; King LR; Golding H
    AIDS; 2007 Feb; 21(4):521-4. PubMed ID: 17301573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
    Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
    Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
    Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
    J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.